INmune Bio rises on applying to start human trial of cancer therapy

Inmune Bio

03/04/2023 18:38

** Shares of drug developer INmune Bio Inc  INMB.O  rise
4.8% to $6.77
    ** Co has submitted an application to the U.S. FDA to start
trials in humans for the use of its therapy INKmune to treat a
type of prostate cancer
    ** The goal of the trial is to define the safety of INKmune
and demonstrate its ability to attack prostate cancer
    ** The trial is expected to take place in four or more
medical centers in the U.S. and will enroll about 30 patients
    ** The 6-month trial will test three doses of INKmune - INMB
    ** Including session's gains, stock up 6.82% YTD

 (Reporting by Sriparna Roy)
 ((Sriparna.Roy@thomsonreuters.com;))